- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02483910
Direct Instruction Language for Learning in Autism Spectrum Disorder (DILLASD)
Efficacy of the Direct Instruction Language for Learning Program to Promote Expressive and Receptive Language in Children With Autism Spectrum Disorder
Study Overview
Status
Conditions
Detailed Description
Autism spectrum disorder (ASD) is a chronic condition of early childhood onset defined by social impairment and repetitive behavior, and affecting 6 to 14 children per 1000 worldwide. Language and communication impairments are among the most common parental concerns about their children with ASD. Untreated language impairments are also predictive of negative long-term outcomes for children with ASD. Direct Instruction-Language for Learning (DI-LL) is a commercially available intervention package that has demonstrated effectiveness in children with language delays due to disadvantaged backgrounds, learning disabilities, or a primary language disorder - but it has not been carefully studied in ASD. This study will test the efficacy of DI-LL in young school-age children with ASD and moderate language delay. DI-LL is a structured, relatively inexpensive intervention designed to promote a range of language skills. It offers a comprehensive, carefully sequenced, brisk-paced program designed to teach a range of language skills to children with language impairments. A key strength of DI-LL is that it can be implemented by educators, psychologists, speech pathologists, behavior therapists without requiring deep expertise in behavioral interventions for ASD.
100 participants, ages 4 to 7 years, 11 months, will be randomly assigned to either DI-LL or Treatment as Usual (TAU). Children randomly assigned to DI-LL will be allowed to continue in ongoing treatments as well. Forty to 42 treatment sessions will occur across 24 weeks with post-treatment follow up visits at Weeks 36 and 48 for subjects in DI-LL. Negative responders to TAU at Week 24 will be offered treatment with DI-LL for 24 weeks. This study is designed to compare DI-LL and TAU on two standardized tests of language function; overall improvement rated by a blinded clinician; and the number of spoken words in a structured laboratory setting via direct observation - again blind to treatment assignment. The intent to treat approach will be used in efficacy analysis and adverse events will be monitored throughout the trial.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Marcus Autism Center - Children's Healthcare of Atlanta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Meets one of the following age and Clinical Evaluation of Language Fundamentals -version 4 (CELF-4) or Clinical Evaluation of Language Fundamentals Preschool-2 (CELF-P) score combinations:
- Males and females > 4 years and < 7 years 11 months of age in with a score < 80 on the CELF-4 or the CELF-P, or
- Males and females > 5 years and < 7 years 11 months of age with a score > 40 on the CELF-4, or
- Males and females > 4 years and < 6 years 5 months of age with a score > 45 CELF-P
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of autism spectrum disorder (ASD) established by clinical assessment, corroborated by the Social Communication Questionnaire and the Autism Diagnostic Observational Schedule
- A score < 80 on the Core Language score of the Clinical Evaluation of Language Fundamentals - 4 if > 6 years 5 months
- Stable educational plan with no planned changes in the intensity of treatment for 6 months
- Stable community treatment program (e.g., speech therapy or occupational therapy) with no planned changes in the treatment for 6 months. (Otherwise eligible subjects with anticipated changes in their community treatment program in the near term will be invited to return when the transition has been accomplished).
- English is spoken in the home and at least one parent is able to read, write and speak English
- Psychotropic medication free or on stable psychotropic medication (no changes in past 6 weeks and no planned changes for the next 6 months)
Exclusion Criteria:
- Presence of a known serious medical condition in the child (based on medical history) that would interfere with child ability to participate in the study
- On examination, child has less than 5 words and unable to imitate at least 5 words
- Children > 6 years 5 months who achieve a score of 40 on the CELF-4 (and judged to be below 40 by the speech language pathologist)
- Presence of a current serious behavioral problem or psychiatric condition in the child that would require another treatment (e.g., psychotic disorder, major depression, moderate or greater aggression, severe disruptive behavior) based on all available information collected at screening
- Currently receiving Direct Instruction Language for Learning (DI-LL) or participation in a DI-LL program in the past 2 years
- Primary mode of communication is a speech generating device (e.g., DynaVox, Gotalk, Proloquo2go)
- On psychotropic medication, but regimen is not stable (Once stabilized, eligibility could be reconsidered.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DI-LL via telehealth
Subjects with autism spectrum disorder (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to receive Direct Instruction-Language for Learning (DI-LL) for 40-48 sessions (roughly twice a week for 24 weeks).
Subjects in this arm will be allowed to continue ongoing treatment during the randomized phase of the study
|
DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another.
The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps.
The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts ("show me" or "point to" or "say the whole thing"), classification, and problem-solving strategies.
For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects.
Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions.
The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons).
These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons.
Other Names:
Usual care including speech therapy in school, community or both
Other Names:
|
Active Comparator: Standard of care delivered via telehealth
Subjects with (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to continue treatment as usual (TAU) for 24 weeks. NOTE: after the randomized trial, subjects who do not show a positive response at Week 24, will be offered Direct Instruction-Language for Learning (DI-LL) for 24 weeks. |
Usual care including speech therapy in school, community or both
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Clinical Evaluation of Language Fundamentals-4 (CELF-4) Score
Time Frame: Baseline, Week 24, Week 48
|
The CELF-4 English Version will be administered to assess the participant's (aged 5-8 years) receptive and expressive language skills.The Core Language score quantifies a participant's overall language performance.
The standard score for the Core Language scale is based on a mean of 100 with a standard deviation of 15 (average range of 85-115).
The higher the score, the better the language function of the participant.
|
Baseline, Week 24, Week 48
|
Change in Clinical Evaluation of Language Fundamentals-Preschool 2 (CELF-P) Score
Time Frame: Baseline, Week 24, Week 48
|
The CELF-P English Version will be administered to assess the preschool-aged participant's receptive and expressive language skills.The Core Language score quantifies a participant's overall language performance.
The standard score for the Core Language scale is based on a mean of 100 with a standard deviation of 15 (average range of 85-115).
The higher the score, the better the language function of the participant.
|
Baseline, Week 24, Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement item of the Clinical Global Impression scale (CGI-I)
Time Frame: Baseline, Week 24, Week 48
|
An independent evaluator, who is blind to treatment assignment, will rate the CGI-I using all available information (e.g.
Parent Nominated Problems and parent ratings) to assess overall improvement from baseline.
It involves a seven-point scale, from 1 "very much improved" through 4 "no change" and 7 "very much worse."
By convention, scores of Much Improved (score of 2) or Very Much Improved (score of 1) are used to define positive response; all other scores result in a classification of negative response.
|
Baseline, Week 24, Week 48
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Growth Scale Value score of the Expressive Vocabulary Test-2 (EVT-2)
Time Frame: Baseline, Week 24
|
The EVT-2 will be administered to measure expressive vocabulary and word retrieval for Standard American English.
The Growth Scale Value (GSV) is used to monitor growth on the EVT.
The GSV is a score that tracks vocabulary over time.
An increase in vocabulary will result in a higher GSV score.
|
Baseline, Week 24
|
Change in Parent-rated Vineland Adaptive Behavior Scales II (Vineland-II)
Time Frame: Baseline, Week 24, Week 48
|
Vineland-II is a measure of adaptive skills in every day life.
Scores may range from 20-160 with an average of 100 with a standard deviation of 15.
Higher scores indicate better adaptive functioning.
|
Baseline, Week 24, Week 48
|
Change in Parenting Stress Index - Short Form (PSI-SF)
Time Frame: Baseline, Week 24
|
The PSI-SF is a parent-report questionnaire of parental stress, parent-child interaction style, and difficult child behaviour that will be used to measure changes in parental stress.
It is a 36-item questionnaire for families of children 12 years of age and younger.
Each of these items is scored using the following 5-point scale: 1 (strongly agree) to 5 (strongly disagree).
The total stress score is a composite of the three subscales.
Higher scores indicate higher parental stress.
|
Baseline, Week 24
|
Change in Caregiver Strain Questionnaire (CGSC)
Time Frame: Baseline, Week 24
|
The CGSC measures the impact of having a child with ASD on the family.
The questionnaire includes 21 items that assess three dimensions of caregiver strain: objective strain, internalized subjective strain, and externalized subjective strain.
Each item is rated on a 5-point scale ranging from 1(not at all a problem) to 5 (very much a problem).
The total score can range from a minimum of 0 - no strain at all, to 110 all items rated as very much.
|
Baseline, Week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lawrence Scahill, MSN, PhD, Emory University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00081144
- AR140208 (Other Identifier: CDMRP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
National Taiwan University HospitalCompletedAutism Spectrum Disorder High-FunctioningTaiwan